Europe Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)
The Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1,467.81 million by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030. ... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1,467.81 million by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030. Rise in Malnutrition and Vitamin Deficiency Among Adults Boosts Europe Sarcopenia Treatment Market Malnutrition is one of the major risk factors for sarcopenia. According to the WHO, approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient. Europe Sarcopenia Treatment Market Overview The sarcopenia treatment market in Europe is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global sarcopenia treatment market and is estimated to register a notable CAGR during the forecast period. Germany is an attractive market due to its innovative approach toward healthcare. According to the Federal Statistical Office, health expenditure in this country amounted to US$ 474 billion in 2021. The awareness of sarcopenia and sarcopenic obesity (SO) is gradually increasing in aging societies across Germany. Sarcopenia and SO are comparatively uncommon (<5%) among German men aged 70 and above. Therefore, an upsurge in the cases of orthopedic disorders, coupled with the rising demand for nutritional supplements, drives the growth of the sarcopenia treatment market in Germany. Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million) Europe Sarcopenia Treatment Market Segmentation The Europe sarcopenia treatment market is categorized into treatment type, distribution channel, and country. Based on treatment type, the Europe sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Europe sarcopenia treatment market share in 2022. In terms of distribution channel, the Europe sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Europe sarcopenia treatment market share in 2022. By country, the Europe sarcopenia treatment market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe sarcopenia treatment market share in 2022. Abbott Laboratories, Amway Corp, Bayer AG, GSK Plc, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, and Sanofi SA are some of the leading companies operating in the Europe sarcopenia treatment market.Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Europe Sarcopenia Treatment Market - Key Industry Dynamics 4.1 Europe Sarcopenia Treatment Market - Key Industry Dynamics 4.2 Market Drivers 4.2.1 Upsurge in Geriatric Population 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults 4.3 Key Market Restraints: 4.3.1 Unavailability of Direct Interventions 4.4 Key Market Opportunities: 4.4.1 Products in Clinical Trial Phases 4.5 Future Trends: 4.5.1 Rising Awareness About Sarcopenia 4.6 Impact of Drivers and Restraints: 5. Sarcopenia Treatment Market - Europe Market Analysis 5.1 Europe Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030 5.2 Europe Sarcopenia Treatment Market Forecast and Analysis 6. Europe Sarcopenia Treatment Market Analysis - By Treatment Type 6.1 Vitamin D and Calcium Supplement 6.1.1 Overview 6.1.2 Vitamin D and Calcium Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 6.2 Protein Supplement 6.2.1 Overview 6.2.2 Protein Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 6.3 Vitamin B12 Supplement 6.3.1 Overview 6.3.2 Vitamin B12 Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 6.4 Others 6.4.1 Overview 6.4.2 Others: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 7. Europe Sarcopenia Treatment Market Analysis - By Distribution Channel 7.1 Pharmacies 7.1.1 Overview 7.1.2 Pharmacies : Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million) 7.2 Retail Channels 7.2.1 Overview 7.2.2 Retail Channels : Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 7.3 Online Channels 7.3.1 Overview 7.3.2 Online Channels : Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million) 7.4 Others 7.4.1 Overview 7.4.2 Others : Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million) 8. Europe Sarcopenia Treatment Market - Country Analysis 8.1 Europe 8.1.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country 8.1.1.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country 8.1.1.2 Germany Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.2.1 Germany Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.2.2 Germany Sarcopenia Treatment Market Breakdown by Distribution Channel 8.1.1.3 France Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.3.1 France Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.3.2 France Sarcopenia Treatment Market Breakdown by Distribution Channel 8.1.1.4 United Kingdom Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.4.1 United Kingdom Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.4.2 United Kingdom Sarcopenia Treatment Market Breakdown by Distribution Channel 8.1.1.5 Italy Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.5.1 Italy Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.5.2 Italy Sarcopenia Treatment Market Breakdown by Distribution Channel 8.1.1.6 Spain Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.6.1 Spain Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.6.2 Spain Sarcopenia Treatment Market Breakdown by Distribution Channel 8.1.1.7 Rest of Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn) 8.1.1.7.1 Rest of Europe Sarcopenia Treatment Market Breakdown by Treatment Type 8.1.1.7.2 Rest of Europe Sarcopenia Treatment Market Breakdown by Distribution Channel 9. Sarcopenia Treatment Market-Industry Landscape 9.1 Overview 9.2 Growth Strategies in the Sarcopenia Treatment Market 9.3 Inorganic Growth Strategies 9.3.1 Overview 9.4 Organic Growth Strategies 9.4.1 Overview 10. Company Profiles 10.1 Abbott Laboratories 10.1.1 Key Facts 10.1.2 Business Description 10.1.3 Products and Services 10.1.4 Financial Overview 10.1.5 SWOT Analysis 10.1.6 Key Developments 10.2 Bayer AG 10.2.1 Key Facts 10.2.2 Business Description 10.2.3 Products and Services 10.2.4 Financial Overview 10.2.5 SWOT Analysis 10.2.6 Key Developments 10.3 Metagenics LLC 10.3.1 Key Facts 10.3.2 Business Description 10.3.3 Products and Services 10.3.4 Financial Overview 10.3.5 SWOT Analysis 10.3.6 Key Developments 10.4 Nestle Health Science SA 10.4.1 Key Facts 10.4.2 Business Description 10.4.3 Products and Services 10.4.4 Financial Overview 10.4.5 SWOT Analysis 10.4.6 Key Developments 10.5 Novartis AG 10.5.1 Key Facts 10.5.2 Business Description 10.5.3 Products and Services 10.5.4 Financial Overview 10.5.5 SWOT Analysis 10.5.6 Key Developments 10.6 Pfizer Inc 10.6.1 Key Facts 10.6.2 Business Description 10.6.3 Products and Services 10.6.4 Financial Overview 10.6.5 SWOT Analysis 10.6.6 Key Developments 10.7 Sanofi SA 10.7.1 Key Facts 10.7.2 Business Description 10.7.3 Products and Services 10.7.4 Financial Overview 10.7.5 SWOT Analysis 10.7.6 Key Developments 10.8 Amway Corp 10.8.1 Key Facts 10.8.2 Business Description 10.8.3 Products and Services 10.8.4 Financial Overview 10.8.5 SWOT Analysis 10.8.6 Key Developments 10.9 GSK Plc 10.9.1 Key Facts 10.9.2 Business Description 10.9.3 Products and Services 10.9.4 Financial Overview 10.9.5 SWOT Analysis 10.9.6 Key Developments 11. Appendix 11.1 About The Insight Partners 11.2 Glossary of Terms
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポートThe Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(distribution channel)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/08 10:26 148.90 円 163.91 円 197.75 円 |